Search PubMed⌕ Search

Biomedical subjects

J Sluetz

Publications and source records attributed to J Sluetz.

2 recordsLinked to original sources

A blood pressure sensor for long-term implantation.

An implantable flow-through blood pressure sensor prototype has been developed for use with an implantable left ventricular assist device (LVAD). This sensor incorporates a flat pressure-sensing diaphragm that is designed to be integral with the wall of a titanium tube that may be placed in the inlet or the outlet flow path of any LVAD. The interior tube flow geometry is transitioned from a round to a D-shape such that flow separation is eliminated. Bench testing of 3 sensors was performed to characterize the sensor. The worst-case results showed a maximum nonlinearity of 0.64 mm Hg, a maximum hysteresis of 0.87 mm Hg, and a maximum nonrepeatability of 0.87 mm Hg. Long-term drift studies of 2 sensors at 193 days and 112 days resulted in a projected annual drift rate of 1.4 and 2.0 mm Hg, respectively. The APEX pressure sensors were evaluated in 5 ventricular assist acute calf experiments in which the sensor outputs were compared with Millar pressure catheter sensors. Pressure output comparisons showed similar pressure tracings. No visible evidence of thrombus formation was found on the APEX sensor compared with thrombus formation found on the Millar catheter at the entrance to the flow path. Tests demonstrated that the blood pressure sensor can accurately measure blood pressure and indicate that it has long-term stability.

Animals↗

Shiley INFUSAID Pump technology.

Totally implantable drug delivery devices have been shown to be safe and effective in the delivery of drugs both systemically and regionally. Applications have been developed for continuous infusions of drugs and are currently being developed for variable flow rates with more sophisticated programmable pumps. Some of the potential benefits of such devices include improved drug efficacy with reduced systemic toxicities, more controlled dosing of drugs, improved quality of life, delivery of proteins and peptides, and individualized patient dosing. The potential exists for creating biofeedback closed loop therapies for diabetes, cardiovascular diseases, and some central nervous system diseases in the future.

Catheterization↗